Welcome to the Newsroom
23 November 2016
WUXI BIOLOGICS and PRIMA sign MOU and Announce Strategic Development and Manufacturing Partnership
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”) and WuXi Biologics (WuXi), a WuXi AppTec group company, and a leading open-access R&D capability and technology platform company dedicated to expedite global biologics development, announced today that a non-binding MOU was signed to form a strategic biologics development and manufacturing partnership.
Article as pdf